Mersana Therapeutics Inc (MRSN)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Mersana Therapeutics Inc (MRSN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013967
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月22日
◆ページ数:46
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Mersana Therapeutics Inc (Mersana) formerly Nanopharma Corp, is a biotechnology company that develops immunoconjugate therapies to improve patients’ lives. The company offers pipeline product XMT-1522, for HER-2 targeted therapies based on its Dolaflexin platform. It utilizes its Fleximer antibody drug conjugation (ADC) platform, Dolaflexin to design ADC’s with drug-to-antibody ratios. Mersana’s Dolaflexin platform offers custom design of an ADC with specific properties to target a particular type of cancer. The company develops immunoconjugates to deliver payloads of anti tumor agents directly to cancerous cells. Its products are developed for multiple cancer indications including gastric cancer and metastatic breast cancer. Mersana is headquartered in Cambridge, Massachusetts, the US.

Mersana Therapeutics Inc (MRSN) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Mersana Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Mersana Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Mersana Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Mersana Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Mersana Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Mersana Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 12
Venture Financing 12
Mersana Therapeutics Raises USD33 Million in Series C Financing Round 12
Mersana Therapeutics Raises USD35 Million in Series B Financing 14
Mersana Therapeutics Secures USD14.51 Million in Venture Funding 15
Mersana Therapeutics Raises US$5 Million In Venture Financing 16
Mersana Therapeutics Raises US$27 Million In Series A-1 Financing 17
Mersana Therapeutics Raises Additional US$4 Million In Venture Financing 19
Partnerships 20
Mersana Expands Co-Development Agreement with Takeda Pharma 20
Mersana Therapeutics Expands Agreement with Takeda Pharma 21
Mersana Therapeutics Enters Into Co-Development Agreement With Endo Pharma 22
Licensing Agreements 23
Takeda Pharma Enters into Agreement with Mersana Therapeutics 23
Mersana Therapeutics Enters into Licensing Agreement with Recepta Biopharma 24
EMD Serono Amends its Licensing Agreement with Mersana Therapeutics 25
Mersana Therapeutics Amends its Licensing Agreement with Adimab 26
Mersana Exercises Option for License Agreement with Millennium 27
Equity Offering 28
Mersana Therapeutics Raises USD75 Million in IPO 28
Mersana Therapeutics Inc – Key Competitors 30
Mersana Therapeutics Inc – Key Employees 31
Mersana Therapeutics Inc – Locations And Subsidiaries 32
Head Office 32
Recent Developments 33
Financial Announcements 33
Nov 09, 2017: Mersana Announces Third Quarter 2017 Financial Results and Provides Business Updates 33
Aug 11, 2017: Mersana Announces Second Quarter 2017 Financial Results and Provides Business Updates 35
Corporate Communications 37
Sep 05, 2017: Mersana Appoints Lawrence M. Alleva to Board of Directors 37
Jan 05, 2017: Mersana Therapeutics Appoints Andrew A. F. Hack, M.D., Ph. D. to Board of Directors 38
Sep 06, 2016: Mersana Therapeutics Appoints Kristen Hege, M.D., to Board of Directors 39
Feb 29, 2016: Dr. Michael J. Kaufman Joins Mersana Therapeutics as Senior Vice President of Chemistry, Manufacturing and Controls 40
Clinical Trials 41
Dec 05, 2016: XMT-1536 Demonstrates Anti-tumor Activity in Lung Cancer Patient-Derived Xenograft Studies 41
Oct 24, 2016: Mersana Announces FDA Clearance of IND Application for Lead Antibody-Drug Conjugate XMT-1522 42
Apr 18, 2016: Mersana Therapeutics New Immunoconjugate Demonstrates Anti-Cancer Activity in Non-Small Cell Lung Cancer and Ovarian Cancer Tumor Models 43
Mar 18, 2016: Mersana Therapeutics to Present Data on New Preclinical Product Candidate XMT-1522 at the 2016 American Association for Cancer Research Annual Meeting 44
Mar 18, 2016: Mersana Therapeutics to Present Data on New Preclinical Product Candidate XMT-1536 at the 2016 American Association for Cancer Research Annual Meeting 45
Appendix 46
Methodology 46
About GlobalData 46
Contact Us 46
Disclaimer 46

List of Tables
Mersana Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Mersana Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Mersana Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Mersana Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Mersana Therapeutics Inc, Deals By Therapy Area, 2011 to YTD 2017 9
Mersana Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Mersana Therapeutics Raises USD33 Million in Series C Financing Round 12
Mersana Therapeutics Raises USD35 Million in Series B Financing 14
Mersana Therapeutics Secures USD14.51 Million in Venture Funding 15
Mersana Therapeutics Raises US$5 Million In Venture Financing 16
Mersana Therapeutics Raises US$27 Million In Series A-1 Financing 17
Mersana Therapeutics Raises Additional US$4 Million In Venture Financing 19
Mersana Expands Co-Development Agreement with Takeda Pharma 20
Mersana Therapeutics Expands Agreement with Takeda Pharma 21
Mersana Therapeutics Enters Into Co-Development Agreement With Endo Pharma 22
Takeda Pharma Enters into Agreement with Mersana Therapeutics 23
Mersana Therapeutics Enters into Licensing Agreement with Recepta Biopharma 24
EMD Serono Amends its Licensing Agreement with Mersana Therapeutics 25
Mersana Therapeutics Amends its Licensing Agreement with Adimab 26
Mersana Exercises Option for License Agreement with Millennium 27
Mersana Therapeutics Raises USD75 Million in IPO 28
Mersana Therapeutics Inc, Key Competitors 30
Mersana Therapeutics Inc, Key Employees 31

★海外企業調査レポート[Mersana Therapeutics Inc (MRSN)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Split Rock Partners, LLC:企業の戦略・SWOT・財務分析
    Split Rock Partners, LLC - Strategy, SWOT and Corporate Finance Report Summary Split Rock Partners, LLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • 3D Systems Corporation:企業の戦略・SWOT・財務分析
    3D Systems Corporation - Strategy, SWOT and Corporate Finance Report Summary 3D Systems Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • 7C Solarparken AG (HRPK):企業の財務・戦略的SWOT分析
    Summary 7C Solarparken AG (7C Solarparken), formerly Colexon Energy AG is a renewable energy company that develops and operates photovoltaic farms. The company operates, maintains, and administrates the photovoltaic power plants with acquisition, financing and optimization of operating assets. Its d …
  • Delta Electricity:企業の戦略的SWOT分析
    Delta Electricity - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …
  • Air Water Inc (4088):企業の財務・戦略的SWOT分析
    Air Water Inc (4088) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • PNE Wind AG (PNE3):電力:M&Aディール及び事業提携情報
    Summary PNE Wind AG (PNE) is a renewable energy company, which develops onshore and offshore wind farms. It has a presence in the wind energy value chain, from site exploration and implementation of approval procedure, financing and turnkey construction to operation and repowering. The company also …
  • Central Glass Co Ltd (4044):企業の財務・戦略的SWOT分析
    Central Glass Co Ltd (4044) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Sumitomo Life Insurance Company:企業のM&A・事業提携・投資動向
    Sumitomo Life Insurance Company - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Sumitomo Life Insurance Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers …
  • Oncolys BioPharma Inc (4588)-製薬・医療分野:企業M&A・提携分析
    Summary Oncolys BioPharma Inc (Oncolys) is a biotechnology company that discovers, and develops treatments for cancer and infectious diseases. The company imports and exports oncolytic viruses, drugs and medicines, and tumor diagnostic agents. Its pharmaceutical pipeline products include OBP-301, OB …
  • The Hongkong and Shanghai Hotels Ltd:企業の戦略・SWOT・財務情報
    The Hongkong and Shanghai Hotels Ltd - Strategy, SWOT and Corporate Finance Report Summary The Hongkong and Shanghai Hotels Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysi …
  • GEDI Gruppo Editoriale SpA (GEDI):企業の財務・戦略的SWOT分析
    GEDI Gruppo Editoriale SpA (GEDI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • Selecta Biosciences Inc (SELB):企業の財務・戦略的SWOT分析
    Summary Selecta Biosciences Inc (Selecta Biosciences) is a biopharmaceutical company that develops immunotherapies and vaccines for the treatment and prevention of human diseases. The company’s pipeline products include SEL-212, SEL-403, SEL-302 and SEL-302. It utilizes synthetic vaccine particle (S …
  • Weight Watchers International, Inc. (WW):企業の財務・戦略的SWOT分析
    Weight Watchers International, Inc. (WW) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths …
  • PeptiDream Inc (4587)-製薬・医療分野:企業M&A・提携分析
    Summary PeptiDream Inc (PeptiDream) is a biopharmaceutical company that discovers and develops constrained peptides, small molecule, and peptide-drug conjugate therapeutics. The company develops peptide discovery platform system (PDPS), a peptide generation and selection platform. Its technologies i …
  • APRIL Group S.A. (APR):企業の財務・戦略的SWOT分析
    APRIL Group S.A. (APR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Bergman & Beving AB:企業の戦略・SWOT・財務情報
    Bergman & Beving AB - Strategy, SWOT and Corporate Finance Report Summary Bergman & Beving AB - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Franz Haniel & Cie. GmbH:企業の戦略的SWOT分析
    Franz Haniel & Cie. GmbH - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products a …
  • Prothena Corp Plc (PRTA)-医療機器分野:企業M&A・提携分析
    Summary Prothena Corp Plc (Prothena) is a biotechnology company that discovers, develops and markets novel antibodies that are indicated for the treatment of diseases associated with amyloid or cell adhesion. The company develops monoclonal antibodies directed specifically at disease-causing protein …
  • Biocare Medical LLC-医療機器分野:企業M&A・提携分析
    Summary Biocare Medical LLC (Biocare) develops and supplies automated immunohistochemistry instrumentation and reagents. The company offers androgen receptor, amyloid A, estrogen receptor, ERG, factor xlla and folate receptor alpha IHC assay kit, among others. It offers on-site training, technical s …
  • CJ Foodville Corporation:企業の戦略・SWOT・財務分析
    CJ Foodville Corporation - Strategy, SWOT and Corporate Finance Report Summary CJ Foodville Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆